Portfolio Risk
Cash runway vs days to next catalyst — spot binary event risk at a glance
| Company | Catalyst | Type | Days | Runway | Impact | Confidence |
|---|---|---|---|---|---|---|
| BOT | SOFDRA quarterly revenue update | Commercial | 8d | CF+ | high | confirmed |
| PNV | NovoSorb BTM US revenue growth | Commercial | 8d | CF+ | medium | confirmed |
| NAN | Trophon installed base growth | Commercial | 8d | CF+ | medium | confirmed |
| ARX | Myriad US revenue growth update | Commercial | 8d | CF+ | medium | confirmed |
| DXB | ACTION3 Blinded Statistical Assumptions Review — Results Due April 2026 | Data Readout | 8d | CF+ | high | confirmed |
| ADO | Wyon AG commercial cell evaluation results (Ultranode 70) | Data Readout | 8d | 3mo | high | expected |
| NYR | PROTECT-MI Phase IIa first patient dosing | Commercial | 8d | 23mo | high | expected |
| CHM | PHASE1/PHASE2 data readout — A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antig | Data Readout | 9d | 2mo | medium | speculative |
| FPH | Trial data readout — The Effect of Home and Hospital Mask Designs on Respiratory Variables in Healthy | Data Readout | 9d | CF+ | medium | speculative |
| RMD | Trial data readout — Circadian Rhythm Monitoring Study | Data Readout | 9d | CF+ | medium | speculative |
| ATX | PHASE1/PHASE2 data readout — ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment | Data Readout | 9d | CF+ | medium | speculative |
| NEU | DAYBUE royalty payment | Commercial | 9d | CF+ | medium | confirmed |
| AGN | ARG-007 Phase 2 SEANCON results at ESOC 2026 (Maastricht) | Conference | 15d | 5mo | medium | confirmed |
| IMU | Azer-cel Phase 1 dose escalation update | Data Readout | 23d | 5mo | high | expected |
| PEB | Trial data readout — Longitudinal Bladder Cancer Study for Tumour Recurrence | Data Readout | 38d | CF+ | medium | speculative |
| PNV | Trial data readout — Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns | Data Readout | 38d | CF+ | medium | speculative |
| IMU | Azer-cel data presentation at ASCO 2026 | Conference | 38d | 5mo | high | confirmed |
| PER | HMBD-002 preclinical data at ASCO 2026 | Conference | 38d | CF+ | medium | confirmed |
| RAC | Bisantrene Phase 1/2 AML interim data | Data Readout | 39d | 2mo | high | expected |
| 4DX | Trial data readout — Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae | Data Readout | 39d | 5mo | medium | speculative |
| TLX | PHASE3 data readout — PSMA PET Combined With MRI for the Detection of PCa | Data Readout | 40d | CF+ | medium | speculative |
| IMM | IMP761 Phase I data at EULAR 2026 | Conference | 43d | CF+ | high | confirmed |
| BOT | BX002 Phase 2 acne topline data | Data Readout | 69d | CF+ | high | expected |
| IMU | Potential capital raise | Financing | 69d | 5mo | medium | speculative |
| TLX | TLX250-CDx FDA submission | Regulatory | 69d | CF+ | high | expected |
| OPT | Sozinibercept Phase 3 wet AMD topline | Data Readout | 69d | CF+ | high | expected |
| 4DX | XV LVAS US reimbursement progress | Commercial | 69d | 5mo | high | expected |
| CU6 | CLARIFY trial enrolment close | Data Readout | 69d | 27mo | high | expected |
| CSL | CSL112 Phase 3 AEGIS-II readout | Data Readout | 69d | CF+ | high | expected |
| CSL | Seqirus flu vaccine season | Commercial | 69d | CF+ | medium | confirmed |
| MSB | Remestemcel-L US BLA resubmission pathway | Regulatory | 69d | 24mo | high | expected |
| PYC | VP-001 Phase 1/2 RP11 further data | Data Readout | 69d | 26mo | high | expected |
| ACW | Xanamem Phase 2 XanaMIA study data | Data Readout | 69d | 3mo | high | expected |
| ANO | ADAPT TAVR first-in-human update | Data Readout | 69d | 0mo | high | expected |
| AVH | Cohealyx I clinical study data readout | Data Readout | 69d | CF+ | medium | expected |
| AVH | 7th MAC reimbursement rate publication | Regulatory | 69d | CF+ | medium | confirmed |
| CYP | CYP-001 Phase 2 aGvHD top-line results | Data Readout | 69d | 7mo | high | confirmed |
| AVH | Final MAC reimbursement coverage | Commercial | 69d | CF+ | high | expected |
| CUV | NEURACTHEL EMA marketing authorization filing | Other | 69d | CF+ | medium | expected |
| EBRDA | WiSE CRT pivotal trial enrolment complete | Data Readout | 69d | 12mo | high | expected |
| PIQ | US PromarkerD revenue ramp (CMS reimbursement live Jan 2026) | Commercial | 69d | 128mo | high | confirmed |
| PIQ | PromarkerEndo Australian commercial launch | Regulatory | 69d | 128mo | medium | expected |
| MYX | RHOFADE generic competition entry | Commercial | 69d | CF+ | high | confirmed |
| NYR | NYR-BI03 Phase 1 brain injury final results | Data Readout | 69d | 23mo | medium | expected |
| RCE | RECCE 327 Phase 3 DFI interim analysis (155 patients) | Data Readout | 69d | 0mo | high | expected |
| ILA | ISLA-101 Phase 2b therapeutic cohort full data package | Data Readout | 69d | 19mo | high | expected |
| CYC | NIH and federal hospital Technegas expansion | Commercial | 69d | CF+ | medium | confirmed |
| LDX | FebriDx US commercial scale-up | Commercial | 69d | CF+ | high | confirmed |
| SOM | Rest Assure clinical study completion | Data Readout | 69d | CF+ | high | expected |
| BDX | Enhanced BREASTESTplus launch (C+D density) | Commercial | 69d | CF+ | high | confirmed |
| ACR | Dapsone 7.5% Gel US launch revenue | Commercial | 69d | 24mo | medium | confirmed |
| SNT | FDA feedback on myelofibrosis development plan | Regulatory | 69d | 11mo | high | expected |
| SNT | Phase 2 MF combo (ruxolitinib) efficacy data readout | Data Readout | 69d | 11mo | high | expected |
| ADO | Battery pipeline lead conversion to JDAs/sales | Commercial | 69d | 3mo | high | speculative |
| IDT | New radiopharmaceutical CDMO contract wins | Commercial | 69d | CF+ | high | speculative |
| BIT | BIT225 licensing/partnership deal (via C14 advisory) | Commercial | 69d | 11mo | high | speculative |
| BIT | HBV preclinical efficacy data from animal models | Data Readout | 69d | 11mo | medium | expected |
| UBI | Aquascout commercial launch | Commercial | 69d | 4mo | high | expected |